marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-12-2024
Axsome Therapeutics Balance Sheet 2011-2024 | AXSM
Annual Balance Sheet Axsome Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-207 M | -106 M | -36.8 M | -133 M | -200 M | -7.06 M | -24.1 M | -26.9 M | -48 M | 1.87 M | 1.74 M | - | - |
Long Term Debt |
178 M | 94.3 M | 49.1 M | 48.3 M | 17.3 M | 3.62 M | 6.66 M | 9.47 M | - | 4.44 M | - | - | - |
Long Term Debt Current |
1.27 M | 425 K | 621 K | 1.22 M | 2.6 M | 3.29 M | 3.27 M | 269 K | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 48.9 M | 17.3 M | 3.62 M | 6.66 M | 9.47 M | - | 5.02 M | - | - | - |
Total Current Liabilities |
139 M | 96.6 M | 23.1 M | 23.4 M | 24.5 M | 10.8 M | 12.2 M | 7.17 M | - | - | - | - | - |
Total Liabilities |
397 M | 222 M | 72.2 M | 72.3 M | 41.8 M | 14.4 M | 18.8 M | 16.6 M | 2.63 M | 5.99 M | 4.13 M | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-836 M | -596 M | -409 M | -279 M | -176 M | -108 M | -76.6 M | -47.6 M | -18.8 M | -8.23 M | -2.23 M | - | - |
Total Assets |
588 M | 331 M | 87.8 M | 186 M | 221 M | 15.4 M | 35.6 M | 38.2 M | 49.1 M | 2.79 M | 2.1 M | - | - |
Cash and Cash Equivalents |
386 M | 201 M | 86.5 M | 184 M | 220 M | 14 M | 34 M | 36.6 M | 48 M | 2.62 M | - | - | - |
Book Value |
191 M | 110 M | 15.6 M | 114 M | 179 M | 938 K | 16.7 M | 21.6 M | 46.4 M | -3.2 M | -2.03 M | - | - |
Total Shareholders Equity |
191 M | 110 M | 15.6 M | 114 M | 179 M | 938 K | 16.7 M | 21.6 M | 46.4 M | -3.2 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Axsome Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
180 M | 179 M | 179 M | 178 M | 177 M | 177 M | - | 94.3 M | 93.9 M | 93.5 M | 49.3 M | 49.1 M | 49.2 M | 48.9 M | 48.6 M | 48.3 M | 48.3 M | 48.3 M | 48.3 M | 17.3 M | 17.3 M | 17.3 M | 17.3 M | 3.62 M | 3.62 M | 3.62 M | 3.62 M | 6.66 M | 6.66 M | 6.66 M | 6.66 M | 9.47 M | 9.47 M | 9.47 M | 9.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
469 M | 445 M | 402 M | 397 M | 331 M | 333 M | - | 222 M | 182 M | 165 M | 73.9 M | 72.2 M | 73.9 M | 71.8 M | 70.6 M | 72.3 M | 72.3 M | 72.3 M | 72.3 M | 41.8 M | 41.8 M | 41.8 M | 41.8 M | 14.4 M | 14.4 M | 14.4 M | 14.4 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | 2.63 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.05 B | -983 M | -904 M | -836 M | -737 M | -675 M | - | -596 M | -535 M | -490 M | -449 M | -409 M | -375 M | -340 M | -308 M | -279 M | -279 M | -279 M | -279 M | -176 M | -176 M | -176 M | -176 M | -108 M | -108 M | -108 M | -108 M | -76.6 M | -76.6 M | -76.6 M | -76.6 M | -47.6 M | -47.6 M | -47.6 M | -47.6 M | -20.4 M | -20.4 M | -20.4 M | -20.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
561 M | 548 M | 546 M | 588 M | 601 M | 612 M | - | 331 M | 339 M | 181 M | 88.6 M | 87.8 M | 117 M | 143 M | 167 M | 186 M | 186 M | 186 M | 186 M | 221 M | 221 M | 221 M | 221 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 38.2 M | 38.2 M | 38.2 M | 38.2 M | 49.1 M | 49.1 M | 49.1 M | 49.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
327 M | 316 M | 331 M | 386 M | 417 M | 437 M | 247 M | 201 M | 228 M | 73.4 M | 84.7 M | 86.5 M | 115 M | 141 M | 165 M | 184 M | 184 M | 184 M | 184 M | 220 M | 220 M | 220 M | 220 M | 14 M | 14 M | 14 M | 14 M | 34 M | 34 M | 34 M | 34 M | 36.6 M | 36.6 M | 36.6 M | 36.6 M | 48 M | 48 M | 48 M | 48 M | 2.62 M | - | - | - | 2.09 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
92.9 M | 103 M | 144 M | 191 M | 270 M | 279 M | - | 110 M | 157 M | 15.2 M | 14.7 M | 15.6 M | 42.7 M | 71.4 M | 96.3 M | 114 M | 114 M | 114 M | 114 M | 179 M | 179 M | 179 M | 179 M | 938 K | 938 K | 938 K | 938 K | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 21.6 M | 21.6 M | 21.6 M | 21.6 M | 46.4 M | 49.1 M | 49.1 M | 49.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
92.9 M | 103 M | 144 M | 191 M | 270 M | 279 M | 112 M | 110 M | 157 M | 15.2 M | 14.7 M | 15.6 M | 42.7 M | 71.4 M | 96.3 M | 114 M | 114 M | 114 M | 114 M | 179 M | 179 M | 179 M | 179 M | 938 K | 938 K | 938 K | 938 K | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 21.6 M | 21.6 M | 21.6 M | 21.6 M | 46.4 M | 46.4 M | 46.4 M | 46.4 M | -3.2 M | - | - | - | -2.03 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency